Cite
HARVARD Citation
Garralda, E. et al. (n.d.). 1510TiPThe GATTO study: A phase I of the anti-EGFR tomuzotuximab (TO) in combination with the anti-MUC1 gatipotuzumab (GAT) in patients with EGFR positive solid tumors. Annals of oncology. p. . [Online].